Introduction {#Sec1}
============

The large external forces responsible for anterior cruciate ligament (ACL) rupture also cause a violent impact between tibial and femoral articular cartilage, which is transferred to bone and results in bone bruise \[[@CR60], [@CR70], [@CR80]\]. Such MRI finding is best diagnosed on fluid-sensitive sequences such as T2-weighted images showing increased signal intensity, with or without decreased signal intensity on T1-weighted images. In addition, short tau inversion recovery (STIR) sequences can provide more sensitive information by suppressing the signal from normal medullary fat \[[@CR55], [@CR62]\]. Sensitivity and specificity of MRI detection have already been documented to be 83/96 and 86/96%, respectively. Moreover, histological studies allowed to correlate these MRI findings to tissue alterations, including microfracture of the subarticular spongiosa, with osteocyte necrosis and empty lacunae, bleeding in the fatty marrow and edema \[[@CR55], [@CR62]\]. Bone bruise associated with ACL rupture has been extensively investigated \[[@CR62], [@CR63]\], but several aspects remain controversial and await evidence on how this MRI finding should be managed while addressing the ligament lesion.

The aim of this systematic review was to document the available evidence on bone bruise associated with ACL lesions, investigating its prevalence and progression, as well as the impact on joint and prognosis, with the hypothesis that bone bruise can influence knee degeneration and patient clinical outcome. This would provide orthopaedic surgeons with evidence-based suggestions in terms of clinical relevance when dealing with patients affected by bone bruise following ACL injury.

Materials and methods {#Sec2}
=====================

A systematic review of the literature was performed on bone bruise associated with ACL injury. This search was conducted on September 4th, 2017, using the following string on three medical electronic databases, PubMed, Web of Science, and the Cochrane Collaboration: \[(subchondral edema) OR (bone bruise) OR (bone marrow edema) OR (bone marrow lesion) OR (bone contusion)\] AND \[(ACL) OR (anterior cruciate ligament)\]. The Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines were used \[[@CR65]\] (Fig. [1](#Fig1){ref-type="fig"}). Two independent authors separately performed the screening process according to preset inclusion and exclusion criteria, study analysis and data tabulation. A final literature summary was obtained by consensus, with disagreements solved by discussion with a third reviewer (GdLF, FN and GF).

Fig. 1PRISMA flowchart of the systematic literature review

First, articles were screened by title and abstract according to the following inclusion criteria: clinical reports of any level of evidence, written in English language, with no time limitation, on the association of bone bruise with ACL lesions. Exclusion criteria were articles written in other languages, preclinical or ex vivo studies, reviews, case reports or clinical studies not evaluating prevalence, progression and impact on the joint and on prognosis. Second, the full texts of the selected articles were screened, with further exclusions according to the previously described criteria. Reference lists from the selected papers were also screened. Relevant data (type of study, no of patients and demographics, injury--MRI time and sequence, follow-up, edema size/grading, edema distribution, prevalence and progression, correlation with other joint lesions and prognosis) were then extracted and collected in a unique database to be analysed for the purposes of the present manuscript. All relevant articles included in this systematic review were studied to investigate three main aspects: the prevalence and progression of bone bruise associated with ACL lesions, its impact on the knee in terms of lesion severity and progression of joint degeneration over time and, finally, the influence of bone bruise on patient prognosis in terms of clinical outcome.

Results {#Sec3}
=======

This systematic review underlined a growing interest on this topic, with an increasing number of papers published over time, more than half in the last 10 years (Fig. [2](#Fig2){ref-type="fig"}). The database search identified 83 papers used for the analysis (a detailed study description is reported in Table [1](#Tab1){ref-type="table"}; Fig. [1](#Fig1){ref-type="fig"}).

Fig. 2The analysis of publications per year shows growing interest on bone bruise in ACL lesions with an increasing number of published studies over time

Table 1Detailed description of the 83 studies selected in this systematic reviewReferencesType of studyNo. of pts, sex, age, mean (range)MRI--injury time sequencesFollow-up (months)Edema size gradingEdema distributionPrevalence and progressionCorrelation with other joint lesions and prognosisMink \[[@CR64]\]NR25, NR, NR≤ 2 weeks, 1.5 T, seq T12NRNR72%NRNRCobby \[[@CR14]\]NR103, 75 M, 28 F, 38 (15--70)NR, 1.5T, seq NSNRNRNRNRNRNRSpeer \[[@CR76]\]Retrospective54, 30 M, 24 F, 28 (14--44)≤ 45 dd, 1.5 T, seq T1, spin density, and T2NRNRNR83%NRNRGraf \[[@CR39]\]NR98, NR, NR≤ 6 weeks; 7 weeks--6 mm; \>6 mm, 1.5 T, seq T1 and T2NRArea30 LTP, 38 LFC 12 MTP, 9 MFC48%NRNRSpindler \[[@CR78]\]Prospective54, NR, 24.5≤ 3 mm, 1.0 or 1.5 T, seq T1, T2 and GENRNR29 LTP, 37 LFC 9 MTP, 3 MFC80%NROsteochondralTung \[[@CR88]\]Retrospective99, 62 M, 37 F, 31 (14--47)≤ 20.5 and 16.9 weeks, 1.5 and 1.0 T, seq T1, T2 and PDNRNR15 LTP, 13 LFC 7 MFC26%NRNRNawata \[[@CR66]\]Retrospective56, 26 M, 30 F, 28 (13--59)≤ 1; 1--12;≥ 12 mm, 1.0 and 1.5 T, seq T2, and PDNRNR17 LTP, 19 LFC 1 MFC36%NRNRGentili \[[@CR37]\]Retrospective89, 62 M, 27 F, 30 (16--75)≤ 1; 1--3; \> 3 mm. 1.5 T, seq T2NRNRNRNRNRNRSpeer \[[@CR77]\]Retrospective42, 20 M, 22 F, 32 (16--58)≤ 1 mm, 0.35, 0.50 and 1.5 T, seq T1, T2 SE and GENRArea34 LTP, 17 LFC 12 MTP, 4 MFCNRNRNRStein \[[@CR79]\]Retrospective20, 10 M, 10 F, 24 (13--48)≤ 4 dd(1 to 23 dd), 1.5 T, seq PD and T240 (24 to 73)NR20 LTP, 13 LFC 3 MTP, 1 PAT100%NRNRZeiss \[[@CR102]\]Retrospective71, 37 M, 34 F, (14--36)≤ 1 mm, 1.5 T, seq GE, T1 and T2NRNRNR36.60%NRNRBrandser \[[@CR9]\]Retrospective74, NR, NR≤ 6 weeks, 1.5 T, seq PD, T2 and T1NRNRNRNRNRNRYeung \[[@CR98]\]NR16, 10 M, 6 F, 25 (13--43)6 dd to 3 y, 0.5 and 1.5 T, seq T1, SE, GE, T2, PD, T1 TSE and TFENRNRNRNRNRNRJohnson \[[@CR48]\]Prospective10, 10 M, 21 (15--36)≤ 2 weeks, 1.5 T, seq T1NRNRNRNRNRNRDimond \[[@CR23]\]Retrospective87, 50 M, 37 F, 29 (16--43)≤ 6 weeks, seq T1, T2 and PDNRNR30 LTP, 24 LFC 4 MTP, 11 MFC68%NRNRLahm \[[@CR56]\]Prospective38, NR, 31NR, seq T1, T2 and STIR5.5 and 40.8NRNR62%NRNRFaber \[[@CR27]\]Retrospective23, 18 M, 5 F, 30 (20--49)≤ 12 dd 1.5 T, seq T1 and T2 FSE72NR23 LTP, 23 LFCNR65%NRKaplan\[[@CR49]\]Retrospective25, 20 M, 5 F, 28 (16--52)≤ 4 weeks, 1.5 T, seq T1, GRE, WE DESS and STIRNRNR25 LTP, 24 LFCNRNRNRLee \[[@CR58]\]Retrospective19, 5 M, 14 F, (5--16)≤ 2; 2--8;\> 8 weeks, 1.5 T, seq T1 and T2NRNRNR68%NRNRJohnson \[[@CR47]\]Prospective40, NR, 18 (15--23)≤ 1 week, NR, seq NS0.2, 0.5, 0.7 and 1NRNRNRNRNRCosta-Paz \[[@CR16]\]Cohort study21, 15 M, 6 F, 31 (20--58)NR34NR11 LTP, 16 LFC 1 MTP, 1 MFCNRNRNRFang \[[@CR28]\]Prospective12, 9 M, 3 F, 18 (17--23)NRNRNR12 LTP, 12 LFCNRNRNRBretlau \[[@CR10]\]Prospective64, 33 M, 31 F, 36 (15--68)≤ 5 dd, 0.1 T, seq T2, PD 3D-GE and STIR4 and 12NR13 LTP, 8 LFC 8 MTP, 5 MFC63%NRNRChen \[[@CR12]\]Retrospective32, 22 M, 10 F, 29\< 6; \> 6 weeks, 1.5 T, seq T1, T, GE and PDNRNRNR63%NRNRFayad \[[@CR29]\]Retrospective84, 42 M, 42 F, (16--39)NS, 1.5 T, seq T1, T2, T2 FS and FSENRNR62 LTP, 50 LFC 35 MTP, 4 MFCNRNRNRDavies \[[@CR19]\]Prospective30, 16 M, 14 F, 28 (17--39)≤ 3.4 weeks, 1.0 T, seq T1, GE and STIR3,2VolumeNRNRNROsteochondralTerzidis \[[@CR83]\]NR255, 197 M, 58 F, 24≤ 1; 2--4 mm, 1.0 T, seq T1 SE, T2 and STIR31NR4 LTP, 29 LFC 4 MTP,5 MFCNRNRNRTiderius \[[@CR87]\]NR24, 14 M, 10 F, 27 (17--40)≤ 3 weeks, 1.5 T, seq T1 GdNRArea6 LTP, 15 LFC96%NROsteochondralFithian \[[@CR33]\]Prospective209, 101 M, 108 F, 39 (16--69)≤ 4 weeks, 1.5 T, seq NR79NRNR53%NRNRVincken \[[@CR91]\]Prospective664, 460 M, 204 F, (16--45)≤ 4 weeks, 0.5 T, seq DSE and 3D T1 GE6NR43 LTP, 44 LFC 31 MTP, 7 MFC 6 PAT18.70%NRLM\
MCL--LCLWu \[[@CR97]\]Pilot study52, 22 M, 30 F, NRNS 1.0 T, seq FSE, FS T1, GE, T1 FSE and T2 FS FSENRBeattie and colleaguesNR7.70%NRNRHernandez-Molina \[[@CR44]\]NR258, 148 M, 110 F, 67NR, 1.5 T, seq SE PD, T2, SE, FS and PD15 and 30NRNR53.80%NROsteochondralNishimori \[[@CR67]\]NR39, 25 M, 14 F, 23 (14--55)≤ 8 dd, 0.3 T, seq SE PD and T2NRNRNR89.70%NROsteochondral\
LMCollins \[[@CR15]\]Retrospective48, 26 M, 22 F, 29≤ 6 mm, 1.5 T, seq FSE PD, FS FSE T2, T2 GRE, CSE PD and CSE T2NRNRNR33%NRNRHanypsiak \[[@CR41]\]Cohort study54, NR, NR≤ 3 weeks, 1.0 T, seq T1, PD, T2, T2 FS and FLASH153 (141--165)NR29 LTP, 37 LFC 9 MTP, 3 MFC80%0%NRAtkinson \[[@CR5]\]Retrospective1546, NR, NR0--4, 4--10, 10--26 and 26--52 weeks, 1.5 T, seq multiplanar FSNRNRNRNRNRMM\
LM\
MCLViskontas \[[@CR92]\]Prospective100, 69 M, 31 F, 29 (13--61)≤ 6 weeks, 1.5 T, seq FS and FSENRArea ICRSNRNRNRNRFrobell \[[@CR36]\]RCT121, 89 M, 32 F, 26≤ 19 ± 6.5 dd, 1.5 T, seq 3D-FLASH, T2 3D-GRE, DETSE and STIRNRVolumeNR98%NRCortical depression fracturesBolbos \[[@CR8]\]Retrospective31, 22 M, 9 F, 31≤ 2 mm, 3 T, seq 2D T2 FS FSE and 3D-SPGRNRArea13 LTP, 9 LFC93%NROsteochondralFrobell \[[@CR35]\]NR58, 42 M, 16 F, 26≤ 5 weeks, 1.5 T, seq 3D-FLASH, T2 3D-GRE, DETSE and STIR3, 6 and 12VolumeNR100%NRNRXiaojuan \[[@CR59]\]Prospective38, 28 M, 10 F, 35 (20--66)≤ 2 mm, 3 T, seq T2 FS FSE, SPGR and 3D MRSINRVolumeNRNRNROsteochondralHalinen \[[@CR40]\]Prospective44, 19 M, 25 F, 39 (21--64)NS, 0.23 T or 1.5 T, seq T1, T2, FSE, DE, SE, FS, PD FSE, PD SE and STIRNRNRNR88.60%NRNRYoon \[[@CR99]\]Retrospective145, 124 M, 21 F, 31 (10--56)≤ 6 weeks; 1.5--3 mm; 3--12 mm; \>12 mm, 1.5 T, seq T1, T2 FS, PD, PD DE and FSNRAreaNR60.70%NRNRDunn \[[@CR26]\]Prospective525, 304 M, 221 F, 23NRNRNRNRNRNRNRQuelard \[[@CR73]\]Prospective217, 139 M, 78 F, 29 (14--62)≤ 6 mm, NR1.5 and 3NR156 LTP, 104 LFC72%NRNRTheologis \[[@CR84]\]Cohort study9, 5 M, 4 F, 35 (27--45)≤ 8 weeks, 3 T, seq T2 FS FSE0.5, 6 and 12VolumeNRNRNROsteochondralFrobell \[[@CR34]\]NR61, 45 M, 16 F, 26NR, 1.5 T, seq FLASH, T2, DETSE and STIR3, 6, 12 and 24Volume58 LTP, 47 LFCNRNRNRYoon \[[@CR101]\]Retrospective80, 58 M, 22 F, 30≤ 8 dd, 1.5 T, seq T1 and T2NRNR50 LTP, 46 LFC 18 MTP, 16 MFC84%NRMM\
LMJelić \[[@CR46]\]NR120, 88 M, 32 F, 31≤ 1 mm, 0.3 T, seq SE T1W1, FS T2W1 and STIRNRNR18 LFC, 4 MFC33%NRMM\
LMPotter \[[@CR72]\]Prospective40, 16 M, 24 F, 37 (15--53)≤ 8 weeks, 1.5 T, seq T2 and CPMG132Area36 LTP, 30 LFCNRNROsteochondralVan Dyck \[[@CR89]\]Retrospective97, 62 M, 35 F, 49 (12--81)≤ 6 weeks, 1.5 and 3.0 T, seq FS TSE WI, SE T1 WI, TSE PD and T2 WINRNRNR41%NRNRKijowski \[[@CR50]\]Retrospective114, 57 M, 57 F, 26≤ 3 weeks, 1.5 and 3.0 T, seq T2 FS FSE and FSE12Volume106 LTP, 88 LFC 57 MTP, 30 MFC96%NRCortical fracturesSzkopek \[[@CR81]\]Prospective17, 10 M, 7 F, 28 (23--34)≤ 2 dd, 1.5 T, seq T2 FS, T1 and 3D Ge T20.5, 1 and 2VolumeNRNRNRNRYoon \[[@CR100]\]Retrospective151, 130 M, 21 F, 31 (10--56)≤ 6 weeks; 6 weeks − 3 mm; 3--12 mm;\> 12 mm, 1.5 T, seq T1, T2 FS, PD, PD DE and FSNRAreaNRNRNRNRBisson \[[@CR7]\]Case control171, 89 M, 82 F, NR≤ 6 weeks, NR, seq NRNRVolume Area145 LTP, 132 LFC 44 MTP, 11 MFC90%NRLMRoemer \[[@CR74]\]NR62, 50 M, 12 F, 26NS, 1.5 T, seq 3D FLASH, T2 GRE, DETSE and STIR12, 24, 36, 48, 60 and 72VolumeNRNRNRNRChang \[[@CR11]\]Retrospective154, 130 M, 24 F, 32 (14--56)\< 3, \> 3 mm, 1.5 T, seq FS T2, T1 and PDNRNRNRNRNRNRWittstein \[[@CR96]\]Case series73, 28 M, 45 F, 16≤ 6 weeks, 1.5 T, seq FS FSE T2NRVolume67 LTP, 70 LFC 45 MTP, 31 MFCNRNRNRWissman \[[@CR94]\]Retrospective7, 5 M, 2 F, NSNR, 1.5--3 T, seq T2, FS FSE and PDNRNR4 LTP, 4 LFC 4 MTP, 4 MFCNRNRNRIllingworth \[[@CR45]\]Retrospective50, 26 M, 24 F, 19≤ 30 dd, 1.5 T, seq T2 TSE FS, PD TSE, T1 SE and TSE PDNRVolume AreaNR86%NRMenisciChin \[[@CR13]\]Retrospective88, 72 M, 16 F, 27≤ 10 weeks, 1.5 T, seq T1 and T2NRNR37 LTP, 43 LFC 23 MTP, 16 MFC, 4 PAT65.90%NRNRWissman \[[@CR95]\]Retrospective132, 82 M, 50 F, 30 (14--70)≤ 4 weeks, 1.5 or 3 T, seq T2, FSE and PDNRNRNRNRNRNRCulvenor \[[@CR17]\]NR111, 71 M, 40 F, 26 (18--50)≤ 12 mm, 3 T, seq 3D PD VISTA, PD TSE and STIR12Area MOAKS15 LTP, 10 LFC 9 MTP, 10 MFC 5 PAT, 22 TRONRNROsteochondralHerbst \[[@CR43]\]Retrospective500, NR, 29≤ 1 mm, NR, seq NRNRArea396 LTP, 257 LFCNRNRNRKim \[[@CR51]\]Retrospective8, 5 M, 3 F, 23 (16--30)≤ 1 mm, 1.5 and 3 T, seq FSENRVolumeNRNRNRNRFilardo \[[@CR32]\]Retrospective134, 98 M, 36 F, 32≤ 6 mm, 1.5 T, seq FSE, PD FS and dual FSE80Area WORMS22 LTP, 12 LFC 4 MTP, 4 MFC 2 PAT55.20%NRNRPezeshki \[[@CR71]\]Prospective175, 149 M, 26 F, \< 45 (18--45)≤ 1 mm, 0.3 T, seq T1 and T2 FS, fluid suppression, GE and T2 SE12AreaNR30,90%NRMM\
MCLKluczynski \[[@CR52]\]Cross sectional59, 59 M, 23≤ 6 weeks, NR, seq NRNRNR48 LTP, 46 LFC 14 MTP, 3 MFCNRNRNRAhn \[[@CR1]\]Retrospective249, 33 M, 216 F, 38 (18--53)≤ 15.4 ± 15.6 (1--52) and 4.2 ± 5.7 (1--50) weeks, 1.5 T, seq T1, T2 and PDNRAreaNRNRNRMeniscal injuriesCulvenor \[[@CR18]\]Prospective93, 56 M, 37 F, 29NS, 3 T, seq PD VISTA, PD TSE and STIR12 and 36AreaNRNR22% (12 mm)NRPalmieri-Smith \[[@CR68]\]Prospective22, 10 M, 12 F, 20≤ 2 weeks, 3 T, seq FSE and T212Area10 LTP, 11 LFC 2 PATNRNROsteochondralKluczynski \[[@CR53]\]Case control384, 209 M, 175 F, NS≤ 6 weeks, NS, seq NRNRNR290 LTP, 251 LFC 105 MTP, 27 MFCNRNRNRSong \[[@CR75]\]Retrospective193, 141 M, 52 F, 32.3 (15--55)≤ 6 weeks, 1.5 T, seq FS and T2NRArea ICRS141 LTP, 117 LFC 41 MTP, 12 MFCNRNRLM\
ALLGong \[[@CR38]\]Prospective54, 31 M, 23 F, 30≤ 55.5 ± 45.3 dd, 3 T, seq CUBE and T26, 12 and 24Volume WORMS33 LTP, 22 LFC 21 MTP, 6 MFC 4 PAT, 1 TRO77,80%20.7% 13.8% 87.2%OsteochondralHelito \[[@CR42]\]Retrospective101, 79 M, 22 F, 33≤ 3 weeks, 1.5 and 3.0 T, seq T1, T2 and PDNRNRNRNRNRNRBerger \[[@CR6]\]Retrospective220, 148 M, 72 F, 34 (16--71)≤ 8 weeks, 1.5 T, seq FS and T2 FSENRVolume WORMS48 LTP, 44 LFC 43 MTP, 5 MFC 7 PATNRNRNRWang \[[@CR93]\]Cross sectional130, 85 M, 45 F, (18--40)NR, 1.5 and 3.0 T, seq T1 and PD FS SE24 and 36Volume130 LTP, 130 LFC 130 MTP, 130 MFCNRNRNRLattermann \[[@CR57]\]Prospective81, NR, 35NR, NS, seq T1, T2 and PD24 and 72Volume Costa-Paz76 LTP, 66 LFC 46 MTP, 20 MFC100%NRLM\
OsteochondralThomas \[[@CR85]\]Descriptive laboratory study35, NR, 20NR, 3 T, seq PD and FSNRArea12 LTP, 12 LFCNRNRNRDriban \[[@CR25]\]Cross sectional121, 89 M, 32 F, 26 (18--35)≤ 4 weeks (19 ± 6.5), 1.5 T, seq DETSENRVolume116 LTP, 101 LFC 101 MTP, 64 MFC96%NRDepression fractureDePhillipo \[[@CR20]\]Case series50, 33 M, 17 F, 30 (14--61)NR, 1.5 and 3.0 T, seq PD, FS and T2NRNR36 MTP76%NRNRTemponi \[[@CR82]\]Retrospective162, NR, NR≤ 1 week, 1.5 T, seq NSNRNR24 LTP, 24 LFC 15 MTP, 9 MFC75%NRSuperior popliteomeniscal fascicleAli \[[@CR2]\]Retrospective25, 15 M, 10 F, 30 (13.5--55)≤ 24 dd (0--10 mm), 1.5 T, seq PDNRNR4 LTP, 2 LFC 4 MTP, 2 MFC60%NRLCL\
MCLThe studies are analysed for type of study, number of initial patients, mean (range) age, sex, follow-up time in months, edema distribution, prevalence, progression and correlation with other joint lesions. Some data discrepancies between overall population and subgroups are due to lack of patient details in some of the studies*NR* not reported, *MFC* medial femoral condyle, *LFC* lateral femoral condyle, *MTP* medial tibial plateau, *LTP* lateral tibial plateau, *TRO* trochlea, *PAT* patella, *LCL* lateral collateral ligament, *MCL* medial collateral ligament, *LM* lateral meniscus, *MM* medial meniscus, *ALL* anterolateral ligament, *ICRS* International Cartilage Research Society, *MOAK* MRI Osteoarthritis Knee Score, *WORMS* Whole-Organ Magnetic Resonance Imaging Score

This systematic review revealed heterogeneous MRI sequences and assessment strategies. Bone bruise was quantified in 43/83 studies with the following approaches: scoring systems were used in 9/43 articles, including WORMS, Costa-Paz, ICRS, Lynch, Beattie and Colleagues score and MOAK, while different parameters such as area/volume of the region of interest (either with absolute or percentage values), depth, signal intensity, distribution and diameter were used as criteria in 42/43 cases to quantify bone bruise. These articles analysed heterogeneous populations, for a total of 10,047 patients, including 2,675 females and 4,665 males (in 11 studies sex was not specified) with different sport participation (four articles focusing on athletes, the others on patients with various activity levels). Age ranged from children (only one study), to young adults and to senior patients (5--81 years).

Bone bruise prevalence and progression {#Sec4}
--------------------------------------

Prevalence of bone bruise ranged from 8 to 98% (reported in 40/83 papers), being higher in the most recent papers (78% in the last 10 years vs. 62% in previous papers). Most of the studies also investigated its distribution in the joint compartments, showing a higher prevalence in the lateral side of the knee (52/55), with lateral tibial plateau (31/43) being the most commonly affected site (Fig. [3](#Fig3){ref-type="fig"}). The evaluation of progression, investigated in 20 studies (seven retrospective, with heterogeneous follow-ups from 2 weeks to 13 years), documented a wide time range: from series showing complete resolution at 2 months, to others documenting persistence of subchondral marrow changes in 65% of the cases at 1 year, or even an increase of bone bruise in one-third of the patients over time.

Fig. 3Percentage of bone bruise distribution in the affected anatomic bone locations. *LTP* lateral tibial plateau, *LFC* lateral femoral condyle, *MTP* medial tibial plateau, *MFC* medial femoral condyle

Some factors were reported to influence frequency, distribution, and progression of bone bruise. Female sex, high BMI, complete vs. partial ACL tears and combined lesions were correlated to higher prevalence, while specific distribution patterns were influenced by injury mechanism, such as pivoting (more lateral), hyperextension (more anterior), motor vehicles accident and patellar dislocation (more anterior with patella involvement), as well as by gender and age (female and older patients presented more lateral lesions). Finally, progression was also influenced by some factors, with slower resolution in the presence of osteochondral lesions and after ACL reconstruction compared to more conservative treatments.

Impact of bone bruise on joint lesion severity and progression {#Sec5}
--------------------------------------------------------------

The severity of joint lesions, investigated in 30/83 studies, was correlated to the presence of bone bruise in 26/30 studies. The most affected tissue was cartilage: osteochondral lesions were reported to correlate significantly in 11/13 studies, ranging from 59% to more than 80% of patients (80% in the lateral tibial plateau or 94% in the lateral femoral condyle) affected by bone bruise; this was followed by meniscus lesions and, less frequently, by collateral ligaments and presence of fractures. Some reports also suggested a possible correlation with other lesions, such as those involving the anterolateral ligament, superior popliteomeniscal fascicle, as well as more abundant and slower resolving effusion. The rim sign, with anteromedial bone bruise distribution, was reported to be associated with greater joint derangement. Moreover, the presence of a \> 1.5 mm notch sign, a bone depression due to more frequent impaction at the lateral femoral condyle after pivoting lesions, was reported to be associated with cartilage lesions and lateral meniscus tears. Finally, few studies evaluated articular samples showing softening, fissuring, with degeneration of chondrocytes and loss of proteoglycans, together with necrosis of osteocytes and empty lacunae in subchondral bone, as well as elevation of COMP degradative fragments, both at cartilage and synovial fluid level. Homeostatic alterations were also supported by changes of synovial fluid, which presented a higher presence of glycosaminoglycans. The impact of bone bruise on joint damage over time was explored, showing (4/8 papers) a correlation of bone bruise with persisting and progressive damage of the articular surface, suggesting early OA development \[[@CR28]\].

Factors influencing lesion severity of joints presenting bone bruise were found in 20 studies, the most frequent being higher bone bruise size and severity, followed by taller patients and higher BMI. A larger bone bruise was also correlated with osteochondral lesion progression.

Influence of bone bruise on the clinical outcome {#Sec6}
------------------------------------------------

Papers evaluating the influence of bone bruise on clinical outcome (19/83) studied 2822 patients, with a follow-up ranging from 1 week to 13 years. Several methods were used: subjective scoring systems, such as KOOS, Tegner, IKDC, SF-36; ADL, Lysholm, Noyes, and VAS, and other evaluation methods including ROM, clinical examination, and gait analysis.

Among these studies, five focused on baseline clinical findings, two of them showing a correlation of bone bruise with higher pain and laxity, especially in case of bone bruise with higher volume and at the medial side. Four studies focused on short-term recovery and documented a longer time to reach normal ROM and non-antalgic gait before ligament reconstruction, with a lower clinical outcome for up to 6 months, especially in case of larger size and medial side bone bruise distribution. Ten studies explored the mid-/long-term outcome: only one was able to document the influence of bone bruise on the mid-term clinical outcome, showing a lower return to sport after ACL reconstruction in joints presenting bone bruise at baseline MRI.

Finally, factors found to influence clinical findings were associated chondral lesions and osteochondral fractures, as well as bone bruise severity, location (lateral distribution with higher instability and ROM limitation, medial distribution with higher pain) and persistence over time; bone bruise detected at MRI performed more than 3 months after trauma was suggestive of a more difficult return to full activity recovery.

Discussion {#Sec7}
==========

The most important finding of this systematic review of the literature is that bone bruise in ACL lesions is a frequently detected MRI finding that entails a more severe joint damage affecting joint degenerative progression.

Several articles have been published over the past 30 years and the interest on this topic is still growing, with an increasing number of studies in the recent past. Nonetheless, the contribution of the existing literature is limited, as most of the findings are accompanied by still open questions, which will be addressed in the following paragraphs. The first factor hindering the possibility to effectively summarize the study results is the lack of a common language in the literature. In fact, besides the overall accepted definition of bone bruise, when looking at lesion assessment and description, the literature showed no common strategy. The sequences used differed among studies, and half of the authors did not even describe the MRI findings observed. Moreover, those who aimed at further assessing the presence of bone bruise, applied heterogeneous methods relying on different grading systems or quantifying area or volume in the affected compartment in either absolute or relative values. The complexity of this scenario is further increased by the heterogeneity of the populations analysed, as well as outcomes and follow-up times investigated. In this light, the evidence on each specific aspect (prevalence, natural history and impact on joint and outcome) is often driven only by few low-quality studies, which explains the current persisting effort of physicians and researchers to further explore the role of bone bruise in ACL lesions.

Prevalence of bone bruise in the MRI of patients affected by ACL lesions has been investigated in most of the selected studies, showing a wide range from 12 to 96%. This heterogeneity can be explained by several factors, such as the differences of the analysed populations in terms of bone bruise joint distribution, mechanism of trauma, age, sex, activity and BMI. Among all, the main factor was the resolution time of the abnormal MRI signal, which makes the presence of bone bruise strongly related to the time passed from injury to MRI examination. To this regard, it is also interesting to observe how the reported prevalence increased in the past few years, which could be explained by different patients included but, possibly, also by the evolution of the MRI technology and sequences. While earlier reports tended to show a swift complete resolution, more recent findings show persistence or even increase of MRI abnormality over time \[[@CR36]\]. However, if from one side, modern MRI can allow a more in-depth study of tissue alterations compared to earlier studies; on the other hand, the clinical significance of this more subtle, but now detectable changes, still remains controversial \[[@CR62]\].

This systematic review evidenced several questions remaining still open, but at the same time it showed an increasing awareness on the importance of bone bruise. The attention on this matter can be better understood looking at the impact of ALC lesions on society: ACL reconstruction is one of the most common procedures in orthopaedics \[[@CR61]\]. Associated injuries and earlier onset of degenerative changes influence the affected knee: high rate (from 10 to 90%) of osteoarthritis development after ACL injury has been reported despite continuous efforts to optimize ACL treatment \[[@CR69]\]. This has prompted researchers to look at possible factors affecting the evolution of joint degeneration.

A correlation between bone bruise and cartilage lesions has been demonstrated, and it is well acknowledged that the presence of cartilage lesions increases with the time elapsed between ACL rupture and reconstruction: chondral lesions may increase the chances of osteoarthritis development, even after ACL surgical repair \[[@CR30]\]. Even though in most cases normal cartilage is initially found during arthroscopy, the osteochondral unit absorbs compression forces during impaction, and this could cause a double long-term mechanism of damage of the articular surface. Cartilage metabolism may be significantly affected, with long-term consequences \[[@CR24]\]. Moreover, abnormality \[[@CR86]\] of subchondral bone may precede and favour cartilage destruction, since the rigid callus resulting from bone fracture may cause cartilage to absorb more of the load force, with abnormal stresses leading to a progressive degeneration of the articular surface \[[@CR62]\]. In ACL reconstructed knees, the cartilage overlying the area of bone bruise presents signs of damage with altered extracellular matrix: cartilage evaluated at 12 months' follow-up with recent MRI sequences showed elevated T1ρ values compared to the surrounding tissue, thus suggesting that despite the resolution of abnormal bone signal, cartilage lesions persist \[[@CR84]\]. These imaging data have been confirmed by histological data, and the analysis of joint samples documented an alteration of the entire joint homeostasis \[[@CR87]\].

Bone bruise in ACL injury is correlated with osteochondral lesions that can act as a catalyst for osteoarthritis even after a successful reconstruction. In this light, it appears logical to suppose that such an important trauma causing these deleterious consequences on joint tissues might also affect clinical prognosis. However, results on this matter are controversial \[[@CR32], [@CR67]\]. The lack of evidence on the correlation between the presence of bone bruise at MRI after trauma and the long-term effect on the joint with the reconstructed ACL may be explained by several factors, starting from the lack of long-term studies, which could better detect the effect on the joint of the cascade started with the initial trauma \[[@CR32]\]. Moreover, current classification systems contribute little towards the understanding of the underlying pathology defined as bone bruise. Relatively less severe trauma causes marrow edema without injury to cells and subchondral bone architecture. However, when the extent of trauma is bigger, trabecular fractures and haemorrhage are seen together with edema, but current MRI sequences and bone bruise definition do not help in distinguishing between these two patterns \[[@CR62]\]. Similarly, it is not always easy to distinguish between bone bruise involving only the marrow with occult fractures not breaching the adjacent cortex, and those involving the osteochondral surface. Moreover, factors predictive of subsequent trabecular fracture development have not been identified yet. In fact, even bone bruise without cortical disruption may represent a region of bone at increased risk for the subsequent development of insufficiency fractures, if bone is not adequately protected during trabecular healing.

Some efforts have been made to identify predicting factors, such as the importance of the localization of the imaging finding and its evolution pattern, with resolution proceeding from periphery to joint margin (opposite to lesions proceeding toward the centre of bone bruise lesion) being suggested to be associated with osteochondral injuries. However, these correlations are mainly related to sporadic evidence \[[@CR19], [@CR34], [@CR55], [@CR90]\]. In fact, most of the studies do not address the different evolution patterns according to possible influencing variables, but rather report overall outcomes on heterogeneous populations. The lack of focus on specific patient populations is another aspect that may hinder a better understanding of the long-term clinical impact, since joint tissue damage can variably affect patients with a different activity level \[[@CR32]\].

Prospective studies are needed to look at the natural history of bone bruise and at identifying factors affecting its radiological and clinical course. At the moment, clinical management remains complicated, both because it is very difficult to identify specific clinical signs and symptoms due to concomitant knee damages (soft tissue lesions and effusion), and because of the lack of correlation between symptoms and imaging findings. Imaging resolution is largely delayed compared to clinical symptomatology \[[@CR4]\], which currently guides clinical management. The understanding of whether and how to protect cartilage (by rest from weight bearing) during initial treatment, when cartilage lacks support from bruised bone \[[@CR21], [@CR54], [@CR55]\], or the development of treatments to address both stiffer long-term tissue repair and altered homeostasis \[[@CR3], [@CR22], [@CR31]\], would likely contribute to overall better results.

During ACL injury, the entire joint undergoes a high-energy trauma, which may alter joint homeostasis and long-term prognosis. In this light, even if no statistical analysis was feasible due to the heterogeneity of the included studies, this systematic review provides evidence-based insights to understand the significance of this articular derangement, which can be of clinical relevance for the orthopaedic surgeon when dealing with patients affected by bone bruise following ACL injury, by underlining that this MRI finding may play an important role in the joint derangement affecting the outcome ACL reconstruction surgery. Future research should aim at better understanding clinical significance, factors predicting resolution or long-term consequences to the affected joint and patient prognosis and, finally, at identifying strategies to restore the overall joint homeostasis rather than just the ligament lesion. This would optimize the management of ACL-injured patients with better long-term results.

Conclusion {#Sec8}
==========

Bone bruise has a high prevalence, with distinct patterns related to the mechanism of injury, and its presence and persistence have been correlated to a more severe joint damage, which may affect the degenerative progression of the entire joint, with recent evidence suggesting possible effects on the long-term clinical outcome. However, prospective long-term studies are needed to better understand the natural history of bone bruise, identifying prognostic factors and targets of specific treatments that could be developed in light of the overall joint derangements accompanying ACL lesions.
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